Introduction
============

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia that is rapidly developing into an epidemic (Savelieva and Camm, [@B43]). It is associated with markedly increased risk of stroke, due to dislocation of thrombi that are most often originated from left atrial appendage (LAA). Although AF is clearly associated with aging, and cardiovascular conditions such as hypertension, mitral valve stenosis, and heart failure, molecular mechanisms underlying its etiology have remained elusive. Recent advances seem to suggest that AF is initiated by atrial structural and electrical remodeling, and that AF itself further augments these responses to perpetuate AF (Savelieva and Camm, [@B43]; Chou and Chen, [@B18]).

The known risk factors for AF have all been linked to oxidative stress, and inflammatory factors such as angiotensin II (Ang II) (Kannel et al., [@B27]; Nakashima et al., [@B40]; Kim et al., [@B28], [@B29]). Ang II is a major vasoconstrictive hormone and its production is elevated in patients with hypertension. It is also involved in modulating cardiac hypertrophy and remodeling. Of note, hypertension is considered the most prevalent risk factor for AF. Atrial structural remodeling can be induced by Ang II, resulting in atrial fibrosis and possibly initiation of AF (Zografos and Katritsis, [@B55]; Tan and Zimetbaum, [@B48]). A meta-analysis of 7 clinical trials involving a total of 24,849 patients receiving ACEIs and/or ARBs for treatment of hypertension, ischemic heart disease, heart failure, or diabetes mellitus demonstrated that ACEIs/ARBs significantly reduces the risk of AF or its recurrence by 28% (Healey et al., [@B24]). Importantly, Ang II is an extremely potent activator of NADPH oxidase (NOX) in the vascular cells (Cai et al., [@B11]; Choi et al., [@B17]; Lassegue and Griendling, [@B33]). NOX-dependent reactive oxygen species (ROS) production leads to nitric oxide ($\text{NO}^{\bullet}$) inactivation and endothelial dysfunction, which underlie pathogenesis of vascular diseases such as hypertension and atherosclerosis (Cai and Harrison, [@B12]; Cai et al., [@B11]; Cai, [@B9],[@B10]). We hypothesize that NOX-derived ROS might be important in mediating Ang II-dependent development of AF. Some interesting data exist to show that hydrogen peroxide increases Kv1.5 current amplitude at voltages corresponding to the action potential repolarization phase and accelerate Kv1.5 channel opening. These changes can reduce the action potential duration, leading to a shortening of the atrial effective refractory period (Caouette et al., [@B13])

To test this hypothesis in human AF, cardiac tissues from heart transplant patients were examined for ROS production and expression of NOX isoforms. Interestingly, we found a specific upregulation of NOX4 that was correlated with H~2~O~2~ overproduction in AF patients. None of the other NOX isoforms were however regulated in AF. AF patients with co-existing hypertension had more than 3-fold increase in H~2~O~2~ production compared to those without. In atrial HL-1 cells, Ang II treatment led to increased AT1 receptor expression, upregulation of NOX4 and increased H~2~O~2~ production. These human and cell culture data together implicate that there might be a novel role of NOX4-derived H~2~O~2~ in mediating Ang II-dependent AF development.

Materials and Methods
=====================

Patient population
------------------

Left atrial appendage tissues isolated from randomly recruited patients undergoing cardiac transplant surgeries were subjected to electron spin resonance (ESR) determination of $\text{O}_{\text{2}}^{\bullet -}$ production, Amplex red determination of H~2~O~2~ production and RT-PCR analysis of NOX gene expression. The study was carried out in a double-blinded fashion. Clinical information was gathered upon completion of laboratory analyses. IRB approval was obtained for these studies.

Electron spin resonance detection of superoxide radical
-------------------------------------------------------

The specific $\text{O}_{\text{2}}^{\bullet -}$ spin trap CMH (0.5 mmol/L; Noxygen) solution was prepared freshly in nitrogen gas bubbled Krebs/HEPES buffer containing diethyldithiocarbamic acid (DETC; 5 μmol/l; Sigma) and deferoxamine (25 μmol/l; Sigma). The LAA homogenates (in 50 mmol/L Tris--HCl, pH 7.4, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, and 1% (v/v) of protease inhibitor cocktail from Sigma) were then mixed with the spin trap solution and loaded into glass capillary (Fisher Scientific) for analysis of $\text{O}_{\text{2}}^{\bullet -}$ production using ESR spectrometer (Bruker), following a similar procedure as we previously published for cultured endothelial cells (Chalupsky and Cai, [@B15]; Gao et al., [@B22],[@B23]) intact mouse aortas (Chalupsky and Cai, [@B15]; Oak and Cai, [@B41]; Gao et al., [@B22]), and tissue homogenates (Lu et al., [@B36]). The ESR settings used were as follows: bio-field 3,410, field sweep 100G, microwave frequency 9.73 GHz, microwave power 13.26 mW, modulation amplitude 9.82G and 512 points of resolution.

Amplex-red assay of hydrogen peroxide production
------------------------------------------------

The LAA lysates \[in 20 mmol/L Tris--HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EGTA, 1 mmol/L EDTA, 1% (v/v) Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L Na~3~VO~4~, 1 mmol/L β-glycerolphosphate, 1 mmol/L PMSF, 1% (v/v) of protease inhibitor cocktail from Sigma\] were analyzed for H~2~O~2~ production using a fluorometric horseradish peroxidase assay (Amplex-Red assay; Molecular Probes). Fluorescence was measured (excitation 530 nm and emission 590 nm) after 1 h of incubation at 37°C in the dark against background fluorescence of buffer. Polyethylene glycol-conjugated catalase (500 U/ml, Sigma) inhibitable fraction reflects specific H~2~O~2~ signal. The rate of H~2~O~2~ production was presented as picomoles per milligram protein per minute after calculation, according to a standard curve generated using fresh H~2~O~2~ in reaction buffer.

RT-PCR analysis of NOX mRNA expression
--------------------------------------

Total RNA was extracted from the LAA using TRIzol (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed in standard fashion with iScript cDNA synthesis Kit (Bio-Rad). The primer sequences used for PCR reactions are summarized in Table [1](#T1){ref-type="table"}. The PCRs were carried out using an iCycler (Bio-Rad) with the protocol of \[(95°C/2 min) (95°C/25 s, 57°C/5 s, 68°C 5 min) × 35 (72°C/10 min)\]. The PCR mix contained GAPDH primers to generate GAPDH amplicon that served as an internal control.

###### 

**Primer sequences for RT-PCR**.

  Gene   Sequence (5′→3′)   
  ------ ------------------ ----------------------------
  NOX1   Forward            CAATCTCTCTCCTGGAATGGCATCCT
         Reverse            CCTGCTGCTCGGATATGAATGGAGAA
  NOX2   Forward            AAGGCTTCAGGTCCACAGAGGAAA
         Reverse            AGACTTTGTATGGACGGCCCAACT
  NOX3   Forward            ACCGTGGAGGAGGCAATTAGACAA
         Reverse            CAGGTTGAAGAAATGCGCCACGAT
  NOX4   Forward            AGCAGAGCCTCAGCATCTGTTCTT
         Reverse            TGGTTCTCCTGCTTGGAACCTTCT
  NOX5   Forward            CCTCCTCATGTTCATCTGCTCCAGTT
         Reverse            AGGAGGTAGGACAGGTGAGTCCAATA

HL-1 cell culture and stimulation by Ang II
-------------------------------------------

The HL-1 cells were obtained as generous gifts from Dr. William Claycomb from Louisiana State University that have been extensively characterized to maintain its differentiated cardiac phenotype using microscopic, genetic, immunohistochemical, electrophysiological, and pharmacological techniques (Claycomb et al., [@B19]; White et al., [@B52]). These beating cells were cultured following exact protocols as established by the Claycomb group and found to keep their phenotype during the 24 h exposure period to Ang II. The confluent cells were kept quiescent in media containing 0.01% FBS overnight and then stimulated with Ang II (100 nmol/L) for 24 h prior to analysis of NOX4 protein expression by Western blot (primary antibody from Abcam) and H~2~O~2~ production by Amplex Red assay. NOX4 mRNA expression from identically treated cells was determined by real-time RT-PCR.

Statistical analysis
--------------------

All data are presented as mean ± SEM. Differences in $\text{O}_{\text{2}}^{\bullet -}$ production, H~2~O~2~ production, and mRNA expression of different NOX isoforms between AF and non-AF groups were compared using *t* tests. ANCOVA were performed to examine the correlation between H~2~O~2~ and NOX4 mRNA expression in patients with and without AF. Statistical significance was set as *p* \< 0.05.

Results
=======

Patient characteristics
-----------------------

Patient characteristics are summarized in Table [2](#T2){ref-type="table"}. Eighteen patients with AF were older than those without (*n* = 17; *p* = 0.047). The gender distribution was not different. Both groups had similar incidence of co-existing cardiovascular conditions including hypertension, diabetes, and coronary artery disease. The percentages of patients receiving treatment of ACEI, AT1RB, calcium blocker or beta blocker were also similar between the two groups (Table [2](#T2){ref-type="table"}). Of note, there was no significant difference in ejection fraction between the AF and non-AF groups. Whereas diastolic blood pressure, total cholesterol and triglyceride levels were not different in the AF vs. non-AF groups, systolic blood pressure (SBP) was higher in the AF patients (Table [2](#T2){ref-type="table"}). ACEI-treated AF group had modestly higher SBP than those of non-AF group receiving ACEI (Table [3](#T3){ref-type="table"}).

###### 

**Patient characteristics**.

  Characteristic                    Non-AF         AF             *p* Value
  --------------------------------- -------------- -------------- -----------
  Age                               47.8 ± 19.2    58.8 ± 11.7    0.047
  Gender (%male)                    70%            61%            0.568
  Hypertension                      59%            39%            0.251
  Diabetes                          29%            28%            0.917
  CAD                               41%            33%            0.643
  Family history of heart disease   65%            44%            0.409
  ACEI Therapy                      53%            44%            0.627
  AT1RB Therapy                     29%            17%            0.384
  Ca^++^ blocker therapy            0%             11%            0.166
  Beta blocker therapy              76%            55%            0.203
  SBP (mmHg)                        107.1 ± 18.3   120.8 ± 13.9   0.033
  DBP (mmHg)                        66.6 ± 12.2    73.8 ± 8.3     0.074
  Ejection fraction (% by ECHO)     20.82 ± 2.3    22.67 ± 2.5    0.586
  TC (mg/dL)                        158.6 ± 33.6   158.0 ± 44.1   0.967
  TG (mg/dL)                        137.8 ± 57.2   144.5 ± 53.6   0.266

*CAD, coronary artery disease; ACEI, angiotensin converting enzyme inhibitor; AT1RB, angiotensin II type-1 (AT1) receptor blocker; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides*.

###### 

**Blood pressure control in patient subgroups**.

  Characteristic   ACEI                    Non-ACEI                                                                      
  ---------------- ----------------------- ------------------ --------------- ----------------------- ------------------ ---------------
  SBP              104.1 ± 16.2            119.1 ± 12.4       0.024           110.6 ± 19.4            123 ± 16.8         0.236
  DBP              68.6 ± 11.0             74.5 ± 9.4         0.236           70.2 ± 10.3             76.4 ± 4.4         0.233
                                                                                                                         
                   **AT1RB**               **Non-AT1RB**                                                                 
                   **Non-AF (*n* = 12)**   **AF (*n* = 4)**   ***p* Value**   **Non-AF (*n* = 13)**   **AF (*n* = 6)**   ***p* Value**
                                                                                                                         
  SBP              120.8 ± 16.6            131 ± 26.9         0.530           101.7 ± 14.3            119.1 ± 11.9       0.003
  DBP              75.1 ± 5.2              78.5 ± 3.5         0.444           67.8 ± 11.4             74.3 ± 7.9         0.120

Reactive oxygen species production
----------------------------------

Among biologically relevant and abundant ROS, $\text{O}_{\text{2}}^{\bullet -}$, and H~2~O~2~ appear to be most important in redox signaling. Whereas $\text{O}_{\text{2}}^{\bullet -}$ predominantly induces endothelial dysfunction by rapidly inactivating nitric oxide ($\text{NO}^{\bullet}$), H~2~O~2~ influences different aspects of endothelial cell function via complex mechanisms. We hypothesize that $\text{O}_{\text{2}}^{\bullet -}$ and H~2~O~2~ also have differential roles in the regulation of cardiac functions. Both species were quantitatively and specifically determined by ESR and Amplex Red assay respectively. Whereas total $\text{O}_{\text{2}}^{\bullet -}$ production was not different between AF and non-AF groups (Figure [1](#F1){ref-type="fig"}A), we found that H~2~O~2~ production was more than doubled in AF patients compared to those without (149.8 ± 26.28 vs. 66.9 ± 7.14 pmol/mg/min, *p* = 0.0055, Figure [1](#F1){ref-type="fig"}B).

![**Superoxide and hydrogen peroxide production in patients with and without atrial fibrillation**. **(A)** Total superoxide production. LAA were homogenated and subsequently analyzed for superoxide production using ESR. **(B)** Hydrogen peroxide production. LAA lysates were analyzed for hydrogen peroxide production using the Amplex Red assay.](fphys-03-00140-g001){#F1}

H~2~O~2~ production in AF patients with co-existing hypertension
----------------------------------------------------------------

Interestingly, AF patients with co-existing hypertension had approximately 3-fold higher H~2~O~2~ production compared to those without (239.0 ± 125.1 vs. 83.6 ± 51.3 pmol/mg/min, *p* = 0.003, Table [4](#T4){ref-type="table"}). Older AF patients (\>50) also had higher tissue levels of H~2~O~2~ compared to those younger AF patients (\<50; 165 ± 118.8 vs. 95.0 ± 64.9 pmol/mg/min), although yet reaching statistical significance. In contrast, hypertension or age had no effect on H~2~O~2~ levels in patients without AF (Table [4](#T4){ref-type="table"}).

###### 

**Hydrogen peroxide levels in patient subgroups**.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Characteristic   Non-AF                   AF                                                                                     
  ---------------- ------------------------ ------------------------ ------- -------------------------- -------------------------- -------
  Hypertension     58.1 ± 25.7 (*n* = 6)    71.7 ± 31.4 (*n* = 11)   0.379   83.6 ± 51.3 (*n* = 11)     239.0 ± 125.1 (*n* = 7)    0.003

  Diabetes         77.4 ± 33.7 (*n* = 12)   51.8 ± 12.5 (*n* = 5)    0.076   151.8 ± 122.7 (*n* = 13)   144.8 ± 87.3 (*n* = 5)     0.909

  CAD              55.6 ± 13.9 (*n* = 10)   71.6 ± 33.3 (*n* = 7)    0.321   155.0 ± 123.8 (*n* = 12)   139.4 ± 91.6 (*n* = 6)     0.789

  Gender           **Male**                 **Female**                       **Male**                   **Female**                 

                   65.9 ± 32.2 (*n* = 13)   69.8 ± 21.6 (*n* = 4)    0.828   136.6 ± 117.9 (*n* = 11)   170.6 ± 105.9 (*n* = 7)    0.544

  Age              \<50\                    \>50\                    0.070   \<50\                      \>50\                      0.278
                   53.3 ± 14.6 (*n* = 8)    79.0 ± 34.5 (*n* = 9)            95.0 ± 64.9 (*n* = 4)      165.5 ± 118.8 (*n* = 14)   
  ----------------------------------------------------------------------------------------------------------------------------------------

Expression of different NOX isoforms and its relationship to H~2~O~2~
---------------------------------------------------------------------

NOX4 is known to either produce H~2~O~2~ directly, or produce $\text{O}_{\text{2}}^{\bullet -}$ in subcellular organelles leaving membrane permeable H~2~O~2~ the sole detectable species (Martyn et al., [@B38]; Lambeth et al., [@B31]; Serrander et al., [@B45]; Chen et al., [@B16]; Block et al., [@B5]; Lassegue and Griendling, [@B33]). Other NOX isoforms however, have been shown to produce $\text{O}_{\text{2}}^{\bullet -}$ directly (Choi et al., [@B17]). Intriguingly, NOX4 mRNA expression was found significantly upregulated in AF patients (Figure [2](#F2){ref-type="fig"}A), which correlated well with a marked increase in H~2~O~2~ production (Figure [2](#F2){ref-type="fig"}B). The expression of NOX1 and NOX2 however, was not different in patients with and without AF (Figures [3](#F3){ref-type="fig"}A,B). NOX3 and NOX5 were not detectable in LAA. We did not find any correlation between ejection fractions and NOX4/H~2~O~2~ levels in both groups. This indicates that severity of heart failure is not linked to NOX4-H~2~O~2~ axis as AF does.

![**Upregulation of NOX4 expression and its correlation with hydrogen peroxide production in patients with atrial fibrillation**. **(A)** NOX4 mRNA expression. NOX4 mRNA expression was determined by RT-PCR analysis and normalization to endogenous amplicon of GAPDH. **(B)** Correlation between NOX4 mRNA expression and hydrogen peroxide production.](fphys-03-00140-g002){#F2}

![**Expression of different NOX isoforms in patients with and without atrial fibrillation**. **(A)** NOX1 mRNA expression. **(B)** NOX2 mRNA expression. NOX1 or NOX2 mRNA expression was determined by RT-PCR analysis and normalization to endogenous amplicon of GAPDH.](fphys-03-00140-g003){#F3}

NOX4 expression and H~2~O~2~ production in Ang II-stimulated HL-1 atrial cells
------------------------------------------------------------------------------

In additional experiments, we examined whether Ang II activates NOX4 in HL-1 atrial cells that have been well characterized to maintain a differentiated, adult cardiomyocyte and atrial cell-like phenotype. In our hand we have also been able to reproduce the culture condition and observe the beating HL-1 cells following the published Claycomb conditions. Of note, the Ang II receptor AT1 was abundantly expressed in these cells, and it was upregulated by Ang II (Figures [4](#F4){ref-type="fig"}A,C). Ang II stimulation resulted in upregulation of NOX4 protein expression and an associated increase in H~2~O~2~ production (Figures [4](#F4){ref-type="fig"}A,B,D). The NOX4 mRNA expression, determined by real-time RT-PCR, was also found upregulated by Ang II in HL-1 cells (Figure [4](#F4){ref-type="fig"}E).

![**NOX4, AT1R expression and hydrogen peroxide production in angiotensin II treated HL-1 atrial cells**. **(A)** Representative Western blots of NOX4 and AT1R expression in Ang II treated HL-1 cells. **(B)** Densitometic grouped data of NOX4 expression in Ang II treated HL-1 cells. **(C)** Densitometic grouped data of NOX4 expression in Ang II treated HL-1 cells. **(D)** Hydrogen peroxide production in Ang II treated HL-1 cells. **(E)** NOX4 mRNA expression in Ang II treated HL-1 cells. Data are represented as Mean ± SEM (N = 4, \**p* \< 0.05 vs. CTRL).](fphys-03-00140-g004){#F4}

Discussion
==========

In the present study, we have discovered that NOX4-derived H~2~O~2~ production is markedly increased in the LAA tissues of AF patients. Hydrogen peroxide production in LAA was 3-fold higher in AF patients with co-existing hypertension than those without. Hypertension is an established risk factor for AF. Recent studies have indicated that H~2~O~2~ regulates electrical properties of isolated rabbit pulmonary vein and atrial cells (Lin et al., [@B35]). Together with the previously characterized role of H~2~O~2~ in myocardial fibrosis, these data suggest that NOX4-derived H~2~O~2~ may play an important role in the development of AF. Indeed, in additional studies utilizing HL-1 atrial cells, we found that Ang II stimulation led to NOX4 upregulation and increased H~2~O~2~ production, further implicating a potential role of NOX4-derived H~2~O~2~ in atrial structural remodeling that is considered an important initiating process of AF.

Aging and hypertension are the best-characterized, potential causal factors for AF. Of significant interest, we found that AF patients with co-existing hypertension had 3-folds higher H~2~O~2~ production compared to those without AF. AF patients that are older (\>50) also had apparently higher H~2~O~2~ production. These observations may further suggest that augmented local cardiac production of H~2~O~2~ is involved in arrhythmogenesis, besides its proinflammatory and prothrombotic effects. On the other hand, AF may have made SBP control more difficult (ACEI-AF group had higher SBP than ACEI-non-AF group), which is likely related to the substantially higher H~2~O~2~ production in hypertensive AF patients. Although H~2~O~2~ can mediate compensatory relaxation under certain conditions such as in the apolipoprotein E deficient atherosclerotic mice (Landmesser et al., [@B32]), excessive H~2~O~2~ is involved in vascular remodeling which could in turn result in stiffer blood vessels to deteriorate hypertension.

We found that LAA $\text{O}_{\text{2}}^{\bullet -}$ production was not different in patients with and without AF. We also found that xanthine oxidase derived $\text{O}_{\text{2}}^{\bullet -}$ was not different between the two groups (data not shown). Xanthine oxidase has been previously shown to play an important role in cardiac $\text{O}_{\text{2}}^{\bullet -}$ production in patients with heart failure. However its role in AF patients has never been previously tested. It is interesting to speculate whereas xanthine oxidase and/or other NOX isoforms is more important for $\text{O}_{\text{2}}^{\bullet -}$ production in heart failure patients, NOX4-derived H~2~O~2~ production is more important in the condition of AF. Of course, this hypothesis needs to be further investigated using larger patient population. Potential regulations of ROS scavenging enzymes such as superoxide dismutases and glutathione peroxidases, under the environment of NOX4-dependent H~2~O~2~ overproduction, would also be interesting to be further investigated.

Our data revealed an innovative role of NOX4 in H~2~O~2~ production in AF patients. Previously NOX1 and NOX4 were found undetectable in RAA (Kim et al., [@B29]). In human LAA, however, we were able to detect abundant NOX1, NOX2, and NOX4 mRNA expression. Only NOX4 mRNA expression was upregulated by AF, which correlated well with overproduction of H~2~O~2~ in AF patients. Accumulating evidence have characterized the relatively newly recognized NOX4 and its ROS-producing activity in various cell types such as endothelial cells (Ago et al., [@B2], [@B1]), vascular smooth muscle (Lassegue et al., [@B34]; Wingler et al., [@B53]; Touyz et al., [@B49]), and kidney cells (Shiose et al., [@B46]; Wingler et al., [@B53]; Chabrashvili et al., [@B14]). Functionally, NOX4 has been implicated in cell differentiation (Clempus et al., [@B20]; Ismail et al., [@B26]; Schroder et al., [@B44]; Xiao et al., [@B54]), cell cycle transition (Sturrock et al., [@B47]), transcriptional activation (Bonello et al., [@B6]), and myofibroblast activation and fibrogenic responses (Hecker et al., [@B25]). In the heart, NOX4 has been shown to be involved in hypertrophy induced cardiac apoptosis and mitochondrial dysfunction (Ago et al., [@B3]), and pressure overload-induced heart failure (Byrne et al., [@B8]; Kuroda et al., [@B30]). Our data add to this rapidly growing knowledge of NOX4 functions, demonstrating a potential role of NOX4 in enhancing H~2~O~2~ production in patients with AF, which might be involved in the pathogenesis of AF. Of note, recent studies have demonstrated an important role of myocardial fibrosis in AF (Everett and Olgin, [@B21]). Therefore, H~2~O~2~ may also contribute to AF via augmentation of myocardial fibrosis as recently reported (Morita et al., [@B39]).

HL-1 cardiomyocytes, derived from atrial cardiac muscle cells from the AT1 mouse atrial cardiomyocyte tumor lineage, maintains the differentiated adult cardiomyocyte phenotype (Claycomb et al., [@B19]). This cell has been proved to possess the organized sarcomere, ion channels, functional receptors, and intracellular signaling proteins so that it contracts spontaneously, divides, generates action potential, and responds to agonists (White et al., [@B52]). Therefore, HL-1 cardiomyocyte has been established as the useful tool to study the cellular and molecular mechanisms underlying cardiac pathophysiologies (Rodriguez-Sinovas et al., [@B42]; Brady et al., [@B7]; Barba et al., [@B4]). In particular, expression of renin--angiotensin system components and Ang II regulation of L-type calcium channel have been characterized in HL-1 cells (Tsai et al., [@B51], [@B50]). Moreover, transcriptional profile regulated by rapid electrical stimulation in HL-1 cells was similar to those from human AF (Mace et al., [@B37]). Therefore, we employed HL-1 cells as the cellular model to investigate whether NOX4 is modulated by Ang II, which has been shown to modulate atrial remodeling and fibrillation. We found AT1R was expressed in HL-1 cells and further upregulated by Ang II treatment. Most importantly, exposure of HL-1 cells to Ang II resulted in increased NOX4 mRNA and protein expression, without affecting NOX1 and NOX2 mRNA levels. This was accompanied by a significant elevation in H~2~O~2~ production.

In summary, our data have uncovered a NOX4-mediated overproduction of H~2~O~2~ in patients with AF. AF patients with hypertension had markedly higher LAA H~2~O~2~ levels compared to those without AF. In addition, H~2~O~2~ has been recently reported to regulate electrical properties of pulmonary vein and atrial cells, where the initiation of ectopic beats is believed to occur to induce AF. It is also known to promote myocardial fibrosis. The modulator of atrial remodeling and fibrosis, Ang II, also significantly upregulated NOX4 expression and H~2~O~2~ production in atrial HL-1 cells. Taken together, these data suggest that NOX4 may play an important role in the pathogenesis of AF.
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